Proxeom is focused on improving cancer survival with technologies for highly-sensitive detection of mutations in circulating cell free DNA enabling early detection, monitoring progression or regression of cancer, detecting metastasis and predicting relapse. By sampling blood and body fluids such as urine, semen, uterine exudates, etc. for mutational signatures of cancer; the non-invasive, liquid biopsy based approach can detect the presence of a tumor in the body as well as provide guidance on therapy.
Location: United States
Investors 2
| Date | Name | Website |
| - | Startup Le... | startuplea... |
| - | MBC BioLab... | mbcbiolabs... |